Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | CPX-351 plus venetoclax in patients with newly-diagnosed high-risk AML

Tapan Kadia • 14 Dec 2023
ASH 2023
Leukemia CPX-351 Cytarabine Daunorubicin Venetoclax

Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks through data presented on a study (NCT03629171) looking at the efficacy and safety of CPX-351 and venetoclax (CPX-ven) in relapsed/refractory (R/R) and newly-diagnosed acute myeloid leukemia (AML). This study showed that the combination is a feasible option for remission induction in this patient group, and is currently ongoing. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Tapan Kadia

Updates on established therapies in AML
19:03
Updates on established therapies in AML
Jessica Altman et al. • 20 Sep 2025
CLIA (cladribine, idarubicin, and cytarabine) plus venetoclax in newly diagnosed AML
2:35
CLIA (cladribine, idarubicin, and cytarabine) plus venetoclax in newly diagnosed AML
Tapan Kadia • 8 Dec 2024
Cladribine with low-dose cytarabine & venetoclax alternating with azacitidine & venetoclax in AML
2:47
Cladribine with low-dose cytarabine & venetoclax alternating with azacitidine & venetoclax in AML
Tapan Kadia • 8 Dec 2024
Pegfilgrastim improves outcomes of intensive chemotherapy plus venetoclax in newly diagnosed AML
2:34
Pegfilgrastim improves outcomes of intensive chemotherapy plus venetoclax in newly diagnosed AML
Tapan Kadia • 8 Dec 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals